Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SLC6A3 Dopaminergic Signaling Subverts Spliceosomal Fidelity to Promote Immune Checkpoint Inhibitor Resistance in Clear Cell Renal Cell Carcinoma [1]

ABSTRACT: Clear cell renal cell carcinoma (ccRCC) remains refractory to immune checkpoint inhibitors (ICIs) despite its high tumor mutational burden, highlighting an urgent need to elucidate tumor-intrinsic mechanisms of immune escape. Here, leveraging lineage tracing and single-cell multi-omic profiling in immunocompetent models, we identify a pre-existing SLC6A3-positive tumor subpopulation that persists following anti-PD-1 therapy and orchestrates immune evasion by exploiting renal dopamine uptake. SLC6A3 overexpression is robustly associated with diminished infiltration of cytotoxic CD8⁺ T cells and myeloid dendritic cells, establishing it as a biomarker of ICI resistance in ccRCC. Mechanistically, SLC6A3-mediated dopamine import disrupts the MHC-I antigen presentation pathway through direct sequestration of the spliceosomal regulator USP39, resulting in aberrant splicing of B2m and Tap1/2 pre-mRNAs and consequent loss of antigenicity. This disconnects high mutational burden from effective immune surveillance, enabling sustained immune escape. Critically, both genetic and pharmacologic inhibition of SLC6A3 restore antigen presentation competency, potentiate CD8⁺ T cell cytotoxicity, and synergize with anti-PD-1 treatment to achieve durable tumor regression in vivo. Our findings redefine dopamine as a tumor-intrinsic immunosuppressant in ccRCC and nominate the SLC6A3-USP39 axis as a tractable target for reversing antigen presentation defects and overcoming microenvironment-driven ICI resistance.

ORGANISM(S): Mus musculus

PROVIDER: GSE316468 | GEO | 2026/01/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SLC6A3 Dopaminergic Signaling Subverts Spliceosomal Fidelity to Promote Immune Checkpoint Inhibitor Resistance in Clear Cell Renal Cell Carcinoma [2]

Project description:Clear cell renal cell carcinoma (ccRCC) remains refractory to immune checkpoint inhibitors (ICIs) despite its high tumor mutational burden, highlighting an urgent need to elucidate tumor-intrinsic mechanisms of immune escape. Here, leveraging lineage tracing and single-cell multi-omic profiling in immunocompetent models, we identify a pre-existing SLC6A3-positive tumor subpopulation that persists following anti-PD-1 therapy and orchestrates immune evasion by exploiting renal dopamine uptake. SLC6A3 overexpression is robustly associated with diminished infiltration of cytotoxic CD8⁺ T cells and myeloid dendritic cells, establishing it as a biomarker of ICI resistance in ccRCC. Mechanistically, SLC6A3-mediated dopamine import disrupts the MHC-I antigen presentation pathway through direct sequestration of the spliceosomal regulator USP39, resulting in aberrant splicing of B2m and Tap1/2 pre-mRNAs and consequent loss of antigenicity. This disconnects high mutational burden from effective immune surveillance, enabling sustained immune escape. Critically, both genetic and pharmacologic inhibition of SLC6A3 restore antigen presentation competency, potentiate CD8⁺ T cell cytotoxicity, and synergize with anti-PD-1 treatment to achieve durable tumor regression in vivo. Our findings redefine dopamine as a tumor-intrinsic immunosuppressant in ccRCC and nominate the SLC6A3-USP39 axis as a tractable target for reversing antigen presentation defects and overcoming microenvironment-driven ICI resistance.

2026-01-21 | GSE316470 | GEO

Boer1985 - Macrophage T cell interaction in anti-tumor response

Project description:In this paper we present a model of the macrophage T lymphocyte interactions that generate an anti-tumor immune response. The modseple cifies i) induction of cytotoxic T lymphocytes, ii) antigen presentation by macrophages, which leads to iii) activation of helper T cells, and iv) production of lymphoid factors, which induce a) cytotoxic macrophages, b) T lymphocyte proliferation, and c) an inflammation reaction. Tumor escape mechanisms (suppression, antigenic heterogeneity) have been deliberately omitted from the model.

2019-11-13 | MODEL1911130003 | BioModels

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Project description:Novel perioperative strategies are needed to reduce recurrence rates in patients undergoing nephrectomy for high-risk, non-metastatic clear cell renal cell carcinoma (ccRCC). We conducted a prospective, phase I trial of neoadjuvant nivolumab prior to nephrectomy in 15 evaluable patients with non-metastatic ccRCC. We leveraged tissue from that cohort to elucidate the effects of PD-1 inhibition on immune cell populations in ccRCC and correlate the evolving immune milieu with anti-PD-1 response. We found that nivolumab durably induces a pro-inflammatory state within the primary tumor, and baseline immune infiltration within the primary tumor correlates with nivolumab responsiveness. Nivolumab increases CTLA-4 expression in the primary tumor, and subsequent nephrectomy increases circulating concentrations of sPD-L1, sPD-L3 (sB7-H3), and s4-1BB. These findings form the basis to consider neoadjuvant immune checkpoint inhibition (ICI) for high-risk ccRCC while the tumor remains in situ and provide the rationale for perioperative strategies of novel ICI combinations.

2023-12-18 | GSE245372 | GEO

Gene expression analysis of non-clear-cell renal cell carcinoma and clear-cell renal cell carcinoma kidney cancers

Project description:Data regarding the clinical outcomes of immune checkpoint inhibitor (ICI) therapy and profiles of the tumor immune microenvironment (TIME) in non-clear-cell renal cell carcinoma (nccRCC) remain limited. Here, we retrospectively compared the effectiveness profiles of first-line ICI combination therapy between patients with clear-cell RCC (ccRCC) and those with nccRCC.

2025-12-10 | GSE312695 | GEO

Expression data from UKRV-Mel-15a melanoma-derived clones resistant to cytolysis mediated by Melan-A/MART1 (26-35) cytotoxic T lymphocytes (CTL).

Project description:Efficient processing of target antigens by the ubiquitin-proteasome-system (UPS) is essential for treatment of cancers by T cell therapies. However, immune escape due to impaired expression of IFN-Î³-inducible components of the antigen presentation machinery and consequent inefficient processing of HLA-dependent tumor epitopes can be one important reason for failure of such therapies. Here, we show that repeated short-term co-cultures of Melan-A/MART-1 tumor antigen-expressing melanoma cells with Melan-A/MART-1 (26-35)-specific CTL led to the generation of clones resistant to CTL-mediated cell death. To determine which of the UPS components and its associated pathways was responsible for CTL escape; three UKRV-Mel-15a clones were subjected to microarray gene expression analysis. Three UKRV-Mel-15a-derived melanoma clones were isolated following three repeated short-term exposures to Melan-A/MART (26-35) CTL and harvested for RNA extraction and hybridization on Affymetrix microarrays.

2015-12-12 | E-GEOD-75929 | biostudies-arrayexpress

Sontag2017 - Dynamic model of immune responses to antigen presentation by tumor or pathogen

Project description:This model of the immune system response to antigen presentation is based on the publication: Eduardo D.Sontag (2017) 'A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination', Cell Systems, 4(2) DOI: 10.1016/j.cels.2016.12.003 Comment: This model is based on the "toy model" as described by Equations 1A-1C from the manuscript and the system represented by Equation 2, which exhibits a type of incoherent feedforward loop (IFFL). Abstract: The immune system must discriminate between agents of disease and an organism’s healthy cells. While the identification of an antigen as self/non-self is critically important, the dynamic features of antigen presentation may also determine the immune system’s response. Here, we use a simple mathematical model of immune activation to explore the idea of antigen discrimination through dynamics. We propose that antigen presentation is coupled to two nodes, one regulatory and one effecting the immune response, through an incoherent feedforward loop and repressive feedback. This circuit would allow the immune system to effectively estimate the increase of antigens with respect to time, a key determinant of immune reactivity in vivo. Our model makes the prediction that tumors growing at specific rates evade the immune system despite the continuous presence of antigens indicating disease, a phenomenon closely related to clinically observed “two-zone tolerance.” Finally, we discuss a plausible biological instantiation of our circuit using combinations of regulatory and effector T cells.

2024-09-02 | BIOMD0000001030 | BioModels

PBAF loss leads to DNA damage induced inflammatory signalling through defective G2/M checkpoint maintenance

Project description:PBRM1 is a subunit of the PBAF (SWI/SNF) chromatin remodelling complex that is mutated in approximately 40% of clear cell renal cell carcinomas (ccRCC). PBRM1 loss has been implicated in the response to immune checkpoint inhibitor (ICI) therapy in ccRCC. However, it is unclear how PBRM1 influences this. DNA damage-induced inflammatory signalling is an important factor determining ICI therapy response. This response is kept in check by the G2/M checkpoint, which prevents progression through mitosis with unrepaired damage. Here, we show that PBRM1 is required for p53-dependent maintenance of the G2/M checkpoint. In its absence, p53-dependent transcriptional upregulation of p21 is delayed, leading to defective repression of DREAM complex targets and premature entry into mitosis. Consequently, DNA damage induced inflammatory signalling pathways are activated by cytosolic DNA. Notably, p53 is infrequently mutated in ccRCC, so PBRM1 mutational status is critical to G2/M checkpoint maintenance following DNA damage in this cancer. These findings have implications for ICI therapy responses in ccRCC.

2022-10-13 | PXD028336 | Pride

Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Project description:<p>Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. The purpose of this study was to investigate whether alterations in genes encoding components of the HLA Class I antigen processing and presentation machinery or interferon signaling pathways play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Whole exome sequencing was performed on tumor samples collected from patients with advanced non-small cell lung cancer at the time of resistance to PD-1 axis inhibitors and on available matched pre-treatment and normal samples. Patient-derived xenografts successfully established from the ICI-resistant samples were also exome sequenced. Additionally, RNA sequencing was performed on cases with sufficient tissue.</p>

| phs001464 | dbGaP

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

Project description:Tumor escape mechanisms for immunotherapy include deficiencies in antigen presentation, diminishing adaptive CD8+ T cell antitumor activity. Although innate NK cells are triggered by loss of MHC class I, their response is often inadequate. To increase tumor susceptibility to both innate and adaptive immune elimination, we performed parallel genome-wide CRISPR-Cas9 screens. This identified all components, RNF31, RBCK1, and SHARPIN, of the linear ubiquitination chain assembly complex (LUBAC). Genetic and pharmacologic ablation of RNF31, an E3 ubiquitin ligase, strongly sensitized melanoma, breast and colorectal cancer cells to both NK and CD8+ T cell killing. This occurred in a TNF-dependent manner, causing loss of A20 and non-canonical IKK complexes from TNF Receptor Complex I. Corroborating this preclinically, a small molecule RNF31 inhibitor sensitized human colon carcinoma organoids to TNF and greatly enhanced immune bystander killing of antigen-loss and antigen presentation machinery-deficient tumor cells. These results merit exploration of RNF31 inhibition as a clinical pharmacological opportunity for immunotherapy-refractory cancers.

2022-05-30 | PXD029489 | Pride

Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear-cell renal cell carcinoma [spatial transcriptomics]

Project description:Immune checkpoint inhibitors (ICI) represent the cornerstone for treatment of patients with metastatic clear-cell renal cell carcinoma (ccRCC). Despite a favorable response for a subset of patients, others experience primary progressive disease highlighting the need to precisely understand plasticity of cancer cells and their crosstalk with the microenvironment to better predict therapeutic response and personalize treatment. Single-cell RNA sequencing of ccRCC at different disease stages and normal adjacent tissue (NAT) from patients identified 46 cell populations, including 5 tumor subpopulations, characterized by distinct transcriptional signatures representing an epithelial to mesenchymal transition gradient and a novel inflamed state. Deconvolution of the tumor and microenvironment signatures in public datasets and in data from the BIONIKK clinical trial (NCT02960906) revealed a strong correlation between mesenchymal-like ccRCC cells and myofibroblastic cancer-associated fibroblasts (myCAFs), which are both enriched in metastases and correlate with poor patient survival. Spatial transcriptomics and multiplex immune staining uncovered spatial proximity of mesenchymal-like ccRCC cells and myCAFs at the tumor-NAT interface. Moreover, enrichment in myCAFs was associated with primary resistance to ICI therapy in the BIONIKK clinical trial. This data highlights the epithelial-mesenchymal plasticity of ccRCC cancer cells and their relationship with myCAFs, a critical component of the microenvironment associated with poor outcome and ICI resistance.

2023-06-26 | GSE210041 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data